ABSI vs AMGN
ABSI: Absci is a clinical-stage drug developer leveraging a generative AI platform to rapidly design and validate novel, differentiated antibody therapeutics for underserved medical conditions. AMGN: A global biotechnology innovator producing biologics, monoclonal antibodies, and small molecules across oncology, cardiovascular, inflammation, and bone health, navigating complex U.S. Medicare pricing pressures.
Side-by-side fundamentals
| Metric | ABSI | AMGN | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $8.24 | $366.05 | |
| Market cap as of 2026-07-23 | $1.4B | $197.7B | |
| P/E as of 2026-07-23 | n/a | 25.34 | |
| PEG as of 2026-07-23 | n/a | 4.93 | |
| Net margin as of 2026-07-23 | -6450.8% | +21.0% | AMGN higher |
| Gross margin as of 2026-07-23 | n/a | +74.0% | |
| Operating margin as of 2026-07-23 | -6723.0% | +28.8% | AMGN higher |
| ROE as of 2026-07-23 | -63.6% | +89.4% | AMGN higher |
| ROA as of 2026-07-23 | -54.7% | +8.6% | AMGN higher |
| Debt / equity as of 2026-07-23 | 0.00 | 6.24 | ABSI lower |
| Revenue growth (YoY) as of 2026-07-23 | -61.9% | +9.1% | AMGN higher |
| Revenue CAGR (3y) SEC XBRL | -1.8% | +11.8% | AMGN higher |
| Dividend yield as of 2026-07-23 | n/a | +2.8% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 2.41 | 0.43 | |
| 1-year return as of 2026-07-22 close | +137.0% | +19.7% | ABSI higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.